Purdue Opioid Victims Face Payout Hurdles from $865M Fund

Settlement Payouts at Risk for Opioid Victims

Purdue Pharma's bankruptcy settlement, which allocates approximately $865 million for individual opioid victims, is proving inaccessible for many. Claimants face daunting paperwork requirements demanding proof that the opioids used were specifically made by Purdue, a hurdle causing widespread claim rejections.

Overview of the Situation

The core issue lies in the requirement to distinguish Purdue's brand-name drugs, like OxyContin, from generic versions. Victims must produce years-old pharmacy or medical records that explicitly name Purdue as the manufacturer, information that is often unavailable or was never recorded. This rule, introduced late in the process, has led to the dismissal of over 40% of the nearly 140,000 claims filed.

Impact on the Settlement Fund

The high disqualification rate directly impacts the distribution of the settlement funds. While the fixed $865 million pool means approved claimants could receive larger payouts, it underscores a critical failure to compensate a significant portion of victims. This situation highlights the administrative complexities that can undermine the objectives of mass tort settlements.

Summary

The Purdue settlement, intended to provide justice, has become a bureaucratic ordeal for many victims. The stringent documentation demands mean a substantial number of individuals harmed by the opioid crisis will not receive any financial relief, raising questions about the efficacy of the compensation process. The final number of approved claims remains a critical factor to watch.

FAQ

Q: Why are many Purdue opioid victim claims being denied?
A: Claims are primarily denied because victims cannot provide specific documentation proving they used Purdue-manufactured opioids, as opposed to generic versions.

Q: How much money did Purdue's settlement allocate for individuals?
A: The settlement earmarked approximately $865 million for a fund to directly compensate individual victims of the opioid crisis.

Source: Investing.com